MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
| Revenue (Most Recent Fiscal Year) | $0.41M |
| Net Income (Most Recent Fiscal Year) | $-12.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 112.95 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1962.14% |
| Net Margin (Trailing 12 Months) | -1962.98% |
| Return on Equity (Trailing 12 Months) | -27.28% |
| Return on Assets (Trailing 12 Months) | -25.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.80 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.24 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 49.22M |
| Free Float | 42.33M |
| Market Capitalization | $67.43M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 0.63 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |